Investor Presentation - First Nine Months of 2016

Novo Nordisk at a glance Investor presentation First nine months of 2016 Slide 23 • Global leader in diabetes care A focused pharmaceutical company with leading positions in diabetes, haemophilia and growth hormone • Significant growth opportunities driven by the diabetes pandemic and fuelled by global presence and strong R&D pipeline • High barriers to entry in biologics • Operating profit growth targeting 5% on average • Earnings conversion to cash targeting 90% Cash generated returned to shareholders Global insulin market leadership Global insulin market share: 46% Europe: Market share 46% Pacific: Market share 47% USA: Market share 37% Region China: Market share 55% International Operations: Market share 55% changing diabetes ●Global/regional headquarter ● Manufacturing • R&D facility Source: IMS MAT August 2016 volume figures novo nordisk

View entire presentation